Cargo Therapeutics (NASDAQ:CRGX) Bolsa

Cargo Therapeutics

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Cargo Therapeutics Inc

News

MAIN

Main Street Estimates Q1 Preliminary Net Investment Income (NII) Of $1.00-$1.02 Per Share And Distributable Net Investment Income Of $1.06-$1.08 Per Share

IonQ and Intellian Technologies, Inc. partner to transform satellite communications with quantum computing
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in the quantum computing and networking industries, announced that it has signed a memorandum of understanding (MoU) with Intellian Technologies, Inc., a leading global provider of satellite communication antennas and ground gateway solutions, to explore how secure quantum networking can transform satellite communications. This memorandum furthers IonQ's work in strategically partnering across South Korea's enterprise, government, and academic sectors and launching initiatives seeking to advance their quantum economy.

IONQ

IonQ Signs MoU With Intellian Technologies To Transform Satellite Communications With Quantum Computing

D. Boral Capital analyst Jesse Sobelson maintains Pineapple Financial (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#AMEX">PAPL</a>) with a Buy and maintains $5 price target.

Price Target

Analyst Ratings

PAPL

D. Boral Capital Maintains Buy on Pineapple Financial, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and maintains $38 price target.

Reiteration

LENZ

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

Jersey Central Power & Light Company, A Subsidiary Of FirstEnergy, Announced An Offer To Exchange Up To $700M Aggregate Principal Amount Of Its Outstanding 5.100% Senior Notes Due 2035 For An Equal Amount Of 5.100% Senior Notes Due 2035

OPRA

Opera Is Adding Its Browser AI, Aria, To Opera Mini, The Android-based Browser With Over 100M Users Worldwide

President Donald Trump&#8217;s tariff policies, which have sent <a href="https://www.benzinga.com/news/25/04/44779286/trumps-tariff-pause-stirs-markets-goldman-sachs-reverses-recession-call-and-more-this-week-in-economy">global markets reeling</a> over the past few weeks, are rooted in his dislike of the U.S. trade deficit.
While his wide-ranging tariffs ignited backlash from economists, the underlying concern isn't new. In 2003, for Fortune Magazine, billionaire investor and CEO of Berkshire Hathaway Inc. (NYSE: <a href="https://www.benzinga.com/stock/brk-a#NYSE" target="_blank" rel="noreferrer noopener">BRK-A</a>) (NYSE: <a href="https://www.benzinga.com/stock/brk-b#NYSE" target="_blank" rel="noreferrer noopener">BRK-B</a>) Warren Buffett offered a novel solution to tackle the country's trade deficit—one that contrasts sharply with Trump's approach.
What Happened: In <a href="https://fortune.com/2016/04/29/warren-buffett-foreign-trade/">the</a> 2003 article, Buffett used the fictional nations of &#8220;Thriftville&#8221; and &#8220;Squanderville,&#8221; to illustrate how trade deficits lead to growing foreign ownership of domestic assets and increasing debt obligations.
Over time, he feared, this dynamic could weaken the country's financial standing and damage its economic independence.
See Also: <a href="https://www.benzinga.com/25/04/44831422/donald-trumps-145-tariffs-on-china-could-disrupt-teslas-cybercab-semi-production-report">Donald Trump&#8217;s 145% Tariffs On China Could Disrupt Tesla&#8217;s Cybercab, Semi Production: Report</a>
Why It Matters: According to the Bureau of Economic Analysis, the U.S. trade deficit stood at 3.1% of GDP in 2024. Buffett's proposed solution was a market-based fixed system he called the "Import Certificate" system.
Unlike traditional tariffs, it would set up a self-regulating mechanism by compelling importers to buy certificates from exporters, thereby incentivizing exports and discouraging excessive imports.
Though he called it "a tariff called by another name," Buffett emphasised that his suggestion avoided political favoritism and <a href="https://www.benzinga.com/25/04/44832771/the-ball-is-in-chinas-court-trump-says-as-white-house-awaits-beijings-call-china-needs-to-make-a-deal-with-us">worldwide retaliation</a>.
With <a href="https://www.benzinga.com/markets/25/04/44831287/trump-administration-imposes-up-to-245-tariff-on-chinese-imports-amid-intensifying-trade-battle">China now facing up to 245% tariffs</a> on specific products as per the latest update from the White House, perhaps it would be worth revisiting Buffett's proposal to de-escalate the ongoing trade war.
Read Next: <a href="https://www.benzinga.com/markets/25/04/44789113/trumps-trade-war-may-lead-to-gops-massive-downfall-in-2026-warn-republican-senators">Trump&#8217;s Trade War May Lead To GOP&#8217;s Massive Downfall In 2026, Warn Republican Senators</a>
Image via Shutterstock

Financial Advisors

Education

Economics

Warren Buffett's 2003 Plan To Fix The Trade Deficit Without A War Deserves A Second Look As US-China Tariff War Continues

Biotech

General

CGEM

Cullinan Therapeutics Receives Approval From European Medicines Agency To Initiate Phase 1 Trial of CLN-978 In Patients With Rheumatoid Arthritis

PPBT

Purple Biotech Announced Today The Publication Of An Independent Study Titled "IRS2 As A Driver Of Brain Metastasis In Colorectal Cancer: A Potential Target For Novel Therapeutic Strategies" In The Peer Reviewed Journal

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and lowers the price target from $26 to $24.

Telsey Advisory Group Maintains Outperform on Albertsons Companies, Lowers Price Target to $24

AMC Theatres Announced That Two Of Its National Flagship Locations, AMC Empire 25 And AMC Lincoln Square 13 In New York City, Have Officially Completed Seven-month, Multi-million Dollar Seating Upgrades

RDHL

RedHill Biopharma Announces The Publication Of In Vivo Date In The Journal Diabetes, Metabolic Syndrome and Obesity In Article Titled 'Opaganib Promotes Weight Loss and Suppresses High-Fat Diet (HFD)-Induced Obesity and Glucose Intolerance'

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Buy and maintains $30 price target.

ADVM

HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

INMB

INmune Bio Announced A Major Intellectual Property Milestone With Respect To Its Next-generation Mesenchymal Stromal Cell (MSC) Product, CORDStrom

The Board of Directors declared a 5% increase in the regular quarterly dividend to $1.10 per share. The dividend is payable June 30, 2025, to shareholders of record at the close of business on June 10, 2025.

Dividends

Travelers Raises Quarterly Dividend By 5% To $1.10/Share From $1.05 Prior

QTTB

Q32 Bio Announced That It Has Dosed The First Patients In Both The Part A Open-label Extension (OLE) And Part B Of The Signal-aa Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Alopecia Areata (AA)

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) reported quarterly earnings of $1.91 per share which beat the analyst consensus estimate of $0.80 by 138.75 percent. This is a 59.28 percent decrease over earnings of $4.69 per share from the same period last year. The company reported quarterly sales of $11.81 billion which beat the analyst consensus estimate of $10.81 billion by 9.25 percent. This is a 5.18 percent increase over sales of $11.23 billion the same period last year.

Earnings

Travelers Companies Q1 EPS $1.91 Beats $0.80 Estimate, Sales $11.81B Beat $10.81B Estimate

The Federal Trade Commission (FTC) has launched a wide-ranging public inquiry into federal regulations that could be stifling competition.
The initiative comes after an executive order from President Donald Trump issued earlier this month, directing federal agencies to identify and eradicate rules that may be protecting dominant players at the cost of new entrants and innovation.
What Happened: On April 14, the FTC issued a Request for Information asking the public to report federal rules that hurt competition. Consumers, workers, businesses, investors, and academics are invited to submit responses and comments by May 27 via Regulations.gov.
See Also: <a href="https://www.benzinga.com/25/04/44821791/meta-platforms-used-buy-or-bury-strategy-to-monopolize-social-media-ftc-says">Meta Used &#8216;Buy Or Bury&#8217; Strategy To Monopolize Social Media, FTC Says</a>
Why It Matters: President Trump's April 9 executive order indicates a major change in federal regulatory policy, targeted at eliminating rules that protect monopolies or distort competition.
By instructing agencies to identify and repeal regulations that "raise prices or reduce choices for consumers," the administration is promoting a more open, innovation-friendly economy.
The FTC's public inquiry boosts this broader agenda by collating examples of how current rules harm competition. If fully implemented, the move could lower costs, catalyse entrepreneurship, and solidify the U.S. position in global trade negotiations.
FTC Chairman Andrew N. Ferguson said in the official press release that regulations that limit innovation and protect dominant players "need to be eliminated or modified."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44799581/no-expiration-date-on-metas-antitrust-case-says-former-ftc-chair-ahead-of-trial">&#8216;No Expiration Date&#8217; On Meta&#8217;s Antitrust Case, Says Former FTC Chair As Trial Begins</a></li>
</ul>
Photo courtesy: T. Schneider / Shutterstock.com

Government

FTC Launches Public Inquiry After Trump Issues Executive Order To Eliminate Anticompetitive Regulations That Favor Monopolies, Raise Consumer Costs

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $8 price target.

IBRX

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $8 Price Target

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has made a bold prediction in light of Tesla's <a href="https://www.benzinga.com/tech/25/04/44787364/tesla-deploys-unsupervised-fsd-at-giga-texas-to-move-cars-from-factory-to-lot">Full Self-Driving (FSD)</a> technology.
What Happened: In a post on social media platform X by Tesla's official handle on Tuesday, the company hailed its vehicles' FSD capabilities and said, ‘One day, it'll drive itself right to your house.'
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One day it'll drive itself right to your house <a href="https://t.co/FGXwgWomHs">https://t.co/FGXwgWomHs</a>
&mdash; Tesla (@Tesla) <a href="https://twitter.com/Tesla/status/1912225160507400611?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Elon Musk reposted the post with a quote, saying, ‘This year.'
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This year <a href="https://t.co/2eCadrXYfd">https://t.co/2eCadrXYfd</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1912243208421023763?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Musk's prediction comes in when Tesla has showcased how its vehicles have logged in over 50,000 driverless miles between its manufacturing facilities in California and Texas.
However, others do not share the billionaire&#8217;s optimism regarding FSD, with Tesla Bull Ross Gerber calling FSD <a href="https://www.benzinga.com/25/03/44068902/tesla-fsd-like-a-12-year-old-driving-compared-to-waymo-says-ross-gerber-warning-uber-has-got-to-be-hurting">‘Like a 12-year-old driving'</a>, compared to the likes of Alphabet's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Waymo.
Waymo has logged more than 20 million autonomous miles and boasts over <a href="https://www.benzinga.com/markets/equities/25/03/44349240/googles-waymo-leads-robotaxi-race-with-2-millon-paid-rides-zoox-challenges-tesla-for-second-spot-as-unsupervised-autonomy-becomes-table-stakes-says-gary-black">2 million paid autonomous rides</a>, establishing a healthy lead in the self-driving race. While Tesla lags behind Waymo, Musk has teased the arrival of Cybercab ride-hailing services in Austin, Texas.
Elsewhere, the Trump administration's tariffs on China could prove to be a problem for <a href="https://www.benzinga.com/25/04/44831422/donald-trumps-145-tariffs-on-china-could-disrupt-teslas-cybercab-semi-production-report">Tesla's Cybercab ambitions</a>. Tesla has also suspended taking new orders for its Model S and X in China.
Price Action: TSLA has experienced a 33% YTD decline in stock value and currently trades for $254.11, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44831960/dan-ives-says-tesla-best-positioned-to-deal-with-tariffs-it-will-ultimately-be-finished-cars-vs-auto-parts">Dan Ives Says Tesla &#8216;Best Positioned&#8217; To Deal With Tariffs: &#8216;It Will Ultimately Be Finished Cars Vs Auto Parts&#8217;</a></li>
</ul>
Image via Shutterstock

Equities

Markets

GOOG

GOOGL

Tesla Touts FSD Capabilities, Elon Says Predicts Cars Will Soon 'Drive Itself Right To Your House'

Press Releases

CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options

Penny Stocks

CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX

Comments

Cargo Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL